Cathrin Brisken

Cathrin Brisken (born in 1967 in Osnabrück, Germany) is a german and swiss medical doctor, researcher, and professor at the École Polytechnique Fédérale de Lausanne (EPFL). Her research focuses on the mechanisms of Hormone in breast cancer development.
Cathrin Brisken obtained a doctoral degree in medicine in 1992 and a Doctor of Philosophy in biophysics in 1993 from the University of Göttingen. She then pursued postdoctoral work in the laboratory of Robert Weinberg (biologist) at the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology. In 2001, she was named assistant professor at the Massachusetts General Hospital Cancer Center. In 2002, she moved to Switzerland to work as an associate scientist at the Swiss Institute for Experimental Cancer Research in Lausanne. In 2005, she was named tenure-track assistant professor at École Polytechnique Fédérale de Lausanne, where she was promoted to associate professor in 2012. In January 2020, she was appointed professor at the Institute of Cancer Research Research in London, where she acts part time and leads the Laboratory of Endocrine Control Mechanisms and the Laboratory of In vivo Modelling. 
In 2015, she co-founded the International Cancer Prevention Institute together with Gian-Paolo Dotto. 
=== Postdoctoral work ===
During her postdoctoral studies in Robert Weinberg's laboratory, Cathrin Brisken combined in vivo tissue reconstitution approaches with mouse genetics, thereby contributing to the understanding that the female sex hormones, Estrogen, progesterone, and prolactin act at sequential stages of mammary gland development, with the mammary epithelium as primary target. She also showed that Steroid hormone act by Paracrine signaling mechanisms and identified specific secreted Wnt signaling pathway as essential mediators of progesterone.
=== As group leader ===
Cathrin Brisken established her own group at EPFL in 2005. Research in her laboratory focuses on the cellular and molecular bases of estrogen, progesterone, and Androgen receptor signaling in the breast and the respective roles of these hormones and hormonally active compounds in breast carcinogenesis. Brisken's laboratory aims to understand how recurrent exposures to endogenous and exogenous hormones contribute to breast cancer development in order to better prevent and treat the disease. 
Brisken's laboratory has proposed novel genetic In vivo approaches and develops Ex vivo and Xenotransplantation models using patient samples to study hormone action in human tissues in normal settings and during disease progression. In 2011, it provided evidence that bisphenol A, a common component of consumer products, has persistent effects on mammary gland development of female embryos whose mothers are exposed to environmentally-relevant doses, pointing to epigenetic events influencing life time breast cancer risk during a perinatal window.
Cathrin Brisken is a member of the Biological Protocol Working Group of the International Breast Cancer Study Group and of the the Pezcoller Symposia Scientific Standing Committee. She served as the Dean of the EPFL Doctoral School from 2012 to 2014, as a member of the Hinterzartener Kreis for cancer research, of the oncology think-tank associated with the German Science Foundation, and of various Swiss, European, and American Association for Cancer Research committees. She was a member of the Women in Cancer Research Council of the American Association for Cancer Research from 2016 to 2020.
Cathrin Brisken is married to fellow cancer researcher Gian-Paolo Dotto and they have three children. She speaks eight languages.
Category:German oncologists
Category:German medical researchers
Category:German Professor